Up-to-date, authoritative and comprehensive, Heart Failure, 4th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald’s Heart Disease helps you make the most of new drug therapies such as angiotensin receptor neprilysin inhibitors (ARNIs), recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Dr. G. Michael Felker and Dr. Douglas Mann, this outstanding reference gives health care providers the knowledge to improve clinical outcomes in heart failure patients.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Dedication - p. v 6. Contributors - p. vi 7. Foreword - p. xiv 8. Preface - p. xv 9. Acknowledgments - p. xvi 10. Braunwald’s Heart Disease Family of Books - p. xix 11. Section I. Basic Mechanisms of Heart Failure - p. xx 12. 1. Molecular Basis of Heart Failure - p. 1 13. 2. Cellular Basis for Heart Failure - p. 30 14. 3. Cellular Basis for Myocardial Regeneration and Repair - p. 43 15. 4. Myocardial Basis for Heart Failure: Role of Cardiac Interstitium - p. 62 16. Section II. Mechanisms of Disease Progression in Heart Failure - p. 75.e7 17. 5. Molecular Signaling Mechanisms of the Renin-Angiotensin System in Heart Failure - p. 76 18. 6. Adrenergic Receptor Signaling in Heart Failure - p. 91 19. 7. Role of Innate Immunity in Heart Failure - p. 103 20. 8. Oxidative Stress in Heart Failure - p. 115 21. 9. Natriuretic Peptides in Heart Failure: Pathophysiologic and Therapeutic Implications - p. 127 22. 10. Systolic Dysfunction in Heart Failure - p. 136 23. 11. Alterations in Ventricular Function: Diastolic Heart Failure - p. 151 24. 12. Alterations in Ventricular Structure: Role of Left Ventricular Remodeling and Reverse Remodeling in Heart Failure - p. 166 25. 13. Alterations in the Sympathetic and Parasympathetic Nervous Systems in Heart Failure - p. 181 26. 14. Alterations in the Peripheral Circulation in Heart Failure - p. 201 27. 15. Alterations in Kidney Function Associated With Heart Failure - p. 214 28. 16. Alterations in Skeletal Muscle in Heart Failure - p. 222 29. 17. Alterations in Cardiac Metabolism in Heart Failure - p. 233 30. Section III. Etiologic Basis for Heart Disease - p. 243.e3 31. 18. Epidemiology of Heart Failure - p. 244 32. 19. Heart Failure as a Consequence of Ischemic Heart Disease - p. 254 33. 20. Heart Failure as a Consequence of Dilated Cardiomyopathy - p. 269 34. 21. Restrictive and Infiltrative Cardiomyopathies and Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy - p. 288 35. 22. Cardiac Amyloidosis - p. 301 36. 23. Heart Failure as a Consequence of Hypertrophic Cardiomyopathy - p. 311 37. 24. Heart Failure as a Consequence of Genetic Cardiomyopathy - p. 322 38. 25. Heart Failure as a Consequence of Hypertension - p. 333 39. 26. Heart Failure as a Consequence of Valvular Heart Disease - p. 347 40. 27. Heart Failure as a Consequence of Congenital Heart Disease - p. 363 41. 28. Heart Failure as a Consequence of Viral and Nonviral Myocarditis - p. 376 42. 29. Heart Failure in the Developing World - p. 385 43. 30. Heart Failure and Human Immunodeficiency Virus - p. 395 44. Section IV. Clinical Assessment of Heart Failure - p. 402.e3 45. 31. Clinical Evaluation of Heart Failure - p. 403 46. 32. Cardiac Imaging in Heart Failure - p. 418 47. 33. Biomarkers and Precision Medicine in Heart Failure - p. 449 48. 34. Hemodynamics in Heart Failure - p. 467 49. Section V. Therapy for Heart Failure - p. 486.e2 50. 35. Disease Prevention in Heart Failure - p. 487 51. 36. Acute Heart Failure - p. 501 52. 37. Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction - p. 520 53. 38. Management of Arrhythmias and Device Therapy in Heart Failure - p. 549 54. 39. Treatment of Heart Failure with Preserved Ejection Fraction - p. 568 55. 40. Management of Heart Failure in Special Populations: Older Patients, Women, and Racial/Ethnic Minority Groups - p. 586 56. 41. Stem Cell-Based and Gene Therapies in Heart Failure - p. 599 57. 42. Neuromodulation in Heart Failure - p. 608 58. 43. Pulmonary Hypertension - p. 617 59. 44. Heart Transplantation - p. 631 60. 45. Circulatory Assist Devices in Heart Failure - p. 649 61. 46. Cardio-Oncology and Heart Failure - p. 665 62. 47. Disease Management and Telemedicine in Heart Failure - p. 674 63. 48. Management of Comorbidities in Heart Failure - p. 687 64. 49. Quality and Outcomes in Heart Failure - p. 697 65. 50. Decision Making and Palliative Care in Advanced Heart Failure - p. 705 66. Index - p. 719
No hay muestra disponible
No hay ficha técnica disponible
Up-to-date, authoritative and comprehensive, Heart Failure, 4th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald’s Heart Disease helps you make the most of new drug therapies such as angiotensin receptor neprilysin inhibitors (ARNIs), recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Dr. G. Michael Felker and Dr. Douglas Mann, this outstanding reference gives health care providers the knowledge to improve clinical outcomes in heart failure patients.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Dedication - p. v 6. Contributors - p. vi 7. Foreword - p. xiv 8. Preface - p. xv 9. Acknowledgments - p. xvi 10. Braunwald’s Heart Disease Family of Books - p. xix 11. Section I. Basic Mechanisms of Heart Failure - p. xx 12. 1. Molecular Basis of Heart Failure - p. 1 13. 2. Cellular Basis for Heart Failure - p. 30 14. 3. Cellular Basis for Myocardial Regeneration and Repair - p. 43 15. 4. Myocardial Basis for Heart Failure: Role of Cardiac Interstitium - p. 62 16. Section II. Mechanisms of Disease Progression in Heart Failure - p. 75.e7 17. 5. Molecular Signaling Mechanisms of the Renin-Angiotensin System in Heart Failure - p. 76 18. 6. Adrenergic Receptor Signaling in Heart Failure - p. 91 19. 7. Role of Innate Immunity in Heart Failure - p. 103 20. 8. Oxidative Stress in Heart Failure - p. 115 21. 9. Natriuretic Peptides in Heart Failure: Pathophysiologic and Therapeutic Implications - p. 127 22. 10. Systolic Dysfunction in Heart Failure - p. 136 23. 11. Alterations in Ventricular Function: Diastolic Heart Failure - p. 151 24. 12. Alterations in Ventricular Structure: Role of Left Ventricular Remodeling and Reverse Remodeling in Heart Failure - p. 166 25. 13. Alterations in the Sympathetic and Parasympathetic Nervous Systems in Heart Failure - p. 181 26. 14. Alterations in the Peripheral Circulation in Heart Failure - p. 201 27. 15. Alterations in Kidney Function Associated With Heart Failure - p. 214 28. 16. Alterations in Skeletal Muscle in Heart Failure - p. 222 29. 17. Alterations in Cardiac Metabolism in Heart Failure - p. 233 30. Section III. Etiologic Basis for Heart Disease - p. 243.e3 31. 18. Epidemiology of Heart Failure - p. 244 32. 19. Heart Failure as a Consequence of Ischemic Heart Disease - p. 254 33. 20. Heart Failure as a Consequence of Dilated Cardiomyopathy - p. 269 34. 21. Restrictive and Infiltrative Cardiomyopathies and Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy - p. 288 35. 22. Cardiac Amyloidosis - p. 301 36. 23. Heart Failure as a Consequence of Hypertrophic Cardiomyopathy - p. 311 37. 24. Heart Failure as a Consequence of Genetic Cardiomyopathy - p. 322 38. 25. Heart Failure as a Consequence of Hypertension - p. 333 39. 26. Heart Failure as a Consequence of Valvular Heart Disease - p. 347 40. 27. Heart Failure as a Consequence of Congenital Heart Disease - p. 363 41. 28. Heart Failure as a Consequence of Viral and Nonviral Myocarditis - p. 376 42. 29. Heart Failure in the Developing World - p. 385 43. 30. Heart Failure and Human Immunodeficiency Virus - p. 395 44. Section IV. Clinical Assessment of Heart Failure - p. 402.e3 45. 31. Clinical Evaluation of Heart Failure - p. 403 46. 32. Cardiac Imaging in Heart Failure - p. 418 47. 33. Biomarkers and Precision Medicine in Heart Failure - p. 449 48. 34. Hemodynamics in Heart Failure - p. 467 49. Section V. Therapy for Heart Failure - p. 486.e2 50. 35. Disease Prevention in Heart Failure - p. 487 51. 36. Acute Heart Failure - p. 501 52. 37. Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction - p. 520 53. 38. Management of Arrhythmias and Device Therapy in Heart Failure - p. 549 54. 39. Treatment of Heart Failure with Preserved Ejection Fraction - p. 568 55. 40. Management of Heart Failure in Special Populations: Older Patients, Women, and Racial/Ethnic Minority Groups - p. 586 56. 41. Stem Cell-Based and Gene Therapies in Heart Failure - p. 599 57. 42. Neuromodulation in Heart Failure - p. 608 58. 43. Pulmonary Hypertension - p. 617 59. 44. Heart Transplantation - p. 631 60. 45. Circulatory Assist Devices in Heart Failure - p. 649 61. 46. Cardio-Oncology and Heart Failure - p. 665 62. 47. Disease Management and Telemedicine in Heart Failure - p. 674 63. 48. Management of Comorbidities in Heart Failure - p. 687 64. 49. Quality and Outcomes in Heart Failure - p. 697 65. 50. Decision Making and Palliative Care in Advanced Heart Failure - p. 705 66. Index - p. 719
No hay muestra disponible
No hay ficha técnica disponible
